

# Steven D Nathan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4192982/steven-d-nathan-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

197  
papers

10,532  
citations

50  
h-index

100  
g-index

293  
ext. papers

13,205  
ext. citations

5  
avg, IF

6.14  
L-index

#	Paper	IF	Citations
197	WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension.. <i>European Respiratory Review</i> , <b>2022</b> , 31,	9.8	3
196	Lung Disease-Related Pulmonary Hypertension. <i>Cardiology Clinics</i> , <b>2022</b> , 40, 77-88	2.5	
195	The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry.. <i>Respiratory Medicine</i> , <b>2022</b> , 196, 106801	4.6	2
194	Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study.. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , <b>2022</b> , 38, e2021032	1.1	
193	Does 1-minute walk test predict results of 6-minute walk test in patients with idiopathic pulmonary fibrosis?. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , <b>2021</b> , 38, e2021005	1.1	1
192	Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension Due to Parenchymal Lung Disease in the INCREASE Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> ,	10.2	2
191	Impact of the new definition for pulmonary hypertension in patients with lung disease: an analysis of the United Network for Organ Sharing database. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 2045894021999960	2.7	2
190	Changes in Neutrophil-Lymphocyte or Platelet-Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	4
189	Development and Validation of a Clinical Diagnostic Scoring System for the Diagnosis of Idiopathic Pulmonary Fibrosis. <i>Annals of the American Thoracic Society</i> , <b>2021</b> , 18, 1803-1810	4.7	0
188	Incidence and prognostic significance of pleural effusions in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211012366	2.7	0
187	Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	18
186	Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211005641	2.7	1
185	Donor derived cell free DNA% is elevated with pathogens that are risk factors for acute and chronic lung allograft injury. <i>Journal of Heart and Lung Transplantation</i> , <b>2021</b> , 40, 1454-1462	5.8	2
184	Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 325, 1841-1851	27.4	12
183	Automated Digital Quantification of Pulmonary Fibrosis in Human Histopathology Specimens. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 607720	4.9	2
182	Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment. <i>Current Opinion in Pulmonary Medicine</i> , <b>2021</b> , 27, 396-404	3	4
181	Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD). <i>Journal of Heart and Lung Transplantation</i> , <b>2021</b> , 40, 488-493	5.8	5

180	Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study. <i>Journal of Heart and Lung Transplantation</i> , <b>2021</b> , 40, 494-503	5.8	5
179	Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 1266-1274	35.1	11
178	Serum levels of small HDL particles are negatively correlated with death or lung transplantation in an observational study of idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , <b>2021</b> , 58,	13.6	3
177	Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 211-220	10.2	20
176	Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 175-181	3.8	2
175	Association Between Anticoagulation and Survival in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation Patient Registry. <i>Chest</i> , <b>2021</b> , 159, 1507-1516	5.3	5
174	Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis. <i>Contemporary Clinical Trials</i> , <b>2021</b> , 100, 106227	2.3	1
173	High-Flow Nasal Cannula Therapy in COVID-19: Using the ROX Index to Predict Success. <i>Respiratory Care</i> , <b>2021</b> , 66, 909-919	2.1	37
172	Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 85-95	35.1	33
171	Inhaled Nitric Oxide via High-Flow Nasal Cannula in Patients with Acute Respiratory Failure Related to COVID-19. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , <b>2021</b> , 15, 11795484211047065	2.4	2
170	Idiopathic pulmonary fibrosis patients with severe physiologic impairment: characteristics and outcomes. <i>Respiratory Research</i> , <b>2021</b> , 22, 5	7.3	2
169	Atraumatic forearm swelling in a patient with poorly controlled asthma. <i>Respiratory Medicine Case Reports</i> , <b>2021</b> , 33, 101454	1.2	
168	Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial. <i>Chest</i> , <b>2021</b> ,	5.3	3
167	Experience of Treating COVID-19 With Remdesivir and Convalescent Plasma in a Resource-Limited Setting: A Prospective, Observational Study. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab391	1	1
166	Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study. <i>Journal of Heart and Lung Transplantation</i> , <b>2021</b> , 40, 822-830	5.8	6
165	Lung Transplantation of COVID-19 Patients. <i>Chest</i> , <b>2021</b> ,	5.3	8
164	Computed Tomography Findings Suggestive of Connective Tissue Disease in the Setting of Usual Interstitial Pneumonia. <i>Journal of Computer Assisted Tomography</i> , <b>2021</b> , 45, 776-781	2.2	0
163	Fostamatinib for the treatment of hospitalized adults with COVID-19 A randomized trial. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	6

162	Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 325-334	59.2	74
161	Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care.. <i>Journal of Heart and Lung Transplantation</i> , <b>2021</b> ,	5.8	2
160	Lung nodules due to in a person with cystic fibrosis.. <i>BMJ Case Reports</i> , <b>2021</b> , 14,	0.9	1
159	A 48-Year-Old South African Woman with Rheumatoid Arthritis and Lung Nodules. <i>Chest</i> , <b>2020</b> , 157, e1511-e1551	3.5	1
158	A Molecular Classifier That Identifies Usual Interstitial Pneumonia in Transbronchial Biopsy Specimens of Patients With Interstitial Lung Disease. <i>Chest</i> , <b>2020</b> , 157, 1391-1392	5.3	0
157	The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , <b>2020</b> , 170, 106068	4.6	5
156	Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	30
155	Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs. <i>PLoS ONE</i> , <b>2020</b> , 15, e0229445	3.7	7
154	A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis. <i>Chest</i> , <b>2020</b> , 158, 637-645	5.3	20
153	FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	6
152	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure. <i>PLoS ONE</i> , <b>2020</b> , 15, e0242651	3.7	33
151	Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture <b>2020</b> ,		16
150	The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. <i>Annals of the American Thoracic Society</i> , <b>2020</b> , 17, 1620-1628	4.7	8
149	Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study. <i>BMC Pulmonary Medicine</i> , <b>2020</b> , 20, 191	3.5	1
148	HRCT evaluation of patients with interstitial lung disease: comparison of the 2018 and 2011 diagnostic guidelines. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2020</b> , 14, 1753466620968496	4.9	3
147	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure <b>2020</b> , 15, e0242651		
146	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure <b>2020</b> , 15, e0242651		
145	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure <b>2020</b> , 15, e0242651		

144	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure <b>2020</b> , 15, e0242651		
143	Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 780-790	35.1	61
142	Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation. <i>EBioMedicine</i> , <b>2019</b> , 40, 541-553	8.8	38
141	Connective tissue disease-associated interstitial lung disease and outcomes after hospitalization: A cohort study. <i>Respiratory Medicine</i> , <b>2019</b> , 154, 1-5	4.6	6
140	Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. <i>Respiratory Medicine</i> , <b>2019</b> , 153, 44-51	4.6	32
139	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 199-208	10.2	53
138	Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 487-496	35.1	61
137	Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. <i>Advances in Therapy</i> , <b>2019</b> , 36, 2910-2926	4.1	8
136	Contemporary optimized practice in the management of pulmonary sarcoidosis. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2019</b> , 13, 1753466619868935	4.9	7
135	Multimodal noninvasive prediction of pulmonary hypertension in IPF. <i>Clinical Respiratory Journal</i> , <b>2019</b> , 13, 567-573	1.7	6
134	Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients. <i>Transplant Infectious Disease</i> , <b>2019</b> , 21, e13166	2.7	21
133	Extracorporeal Membrane Oxygenation as a Bridge to Initial Medical Therapy in a Patient With Decompensated Pulmonary Arterial Hypertension Presenting With Biventricular Failure. <i>Journal of Medical Cases</i> , <b>2019</b> , 10, 260-263	0.2	
132	Pulmonary hypertension due to interstitial lung disease. <i>Current Opinion in Pulmonary Medicine</i> , <b>2019</b> , 25, 459-467	3	12
131	Critical Care of the Adult Patient With Cystic Fibrosis. <i>Chest</i> , <b>2019</b> , 155, 202-214	5.3	14
130	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 227-238	35.1	55
129	Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. <i>Chest</i> , <b>2019</b> , 155, 712-719	5.3	11
128	Pulmonary hypertension in chronic lung disease and hypoxia. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	231
127	A 24-Year-Old Woman With Precipitous Respiratory Failure After Lung Transplantation. <i>Chest</i> , <b>2018</b> , 153, e53-e56	5.3	5

126	Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 925-932	5.8	40
125	Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design. <i>Respiratory Medicine</i> , <b>2018</b> , 138, 13-20	4.6	22
124	Single vs. bilateral lung transplantation: when and why. <i>Current Opinion in Organ Transplantation</i> , <b>2018</b> , 23, 316-323	2.5	12
123	RNAseq analysis of bronchial epithelial cells to identify COPD-associated genes and SNPs. <i>BMC Pulmonary Medicine</i> , <b>2018</b> , 18, 42	3.5	16
122	The Value and Application of the 6-Minute-Walk Test in Idiopathic Pulmonary Fibrosis. <i>Annals of the American Thoracic Society</i> , <b>2018</b> , 15, 3-10	4.7	30
121	Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views. <i>Respiration</i> , <b>2018</b> , 96, 514-524	3.7	27
120	Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials. <i>BMJ Open Respiratory Research</i> , <b>2018</b> , 5, e000323	5.6	20
119	Novel management strategies for idiopathic pulmonary fibrosis. <i>Expert Review of Respiratory Medicine</i> , <b>2018</b> , 12, 831-842	3.8	5
118	Exercise pulmonary haemodynamic response predicts outcomes in fibrotic lung disease. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	4
117	Clinical management and outcomes of patients with Hermansky-Pudlak syndrome pulmonary fibrosis evaluated for lung transplantation. <i>PLoS ONE</i> , <b>2018</b> , 13, e0194193	3.7	20
116	Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	11
115	The Diagnosis and Management of Airway Complications Following Lung Transplantation. <i>Chest</i> , <b>2017</b> , 152, 627-638	5.3	40
114	Early postoperative management after lung transplantation: Results of an international survey. <i>Clinical Transplantation</i> , <b>2017</b> , 31, e12985	3.8	5
113	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 1661-1670	10.2	38
112	sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension. <i>Respiratory Medicine</i> , <b>2017</b> , 122 Suppl 1, S28-S34	4.6	6
111	A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 140, 1716-1718	11.5	14
110	Ventricular Diastolic Pressure Ratio as a Marker of Treatment Response in Pulmonary Hypertension. <i>Chest</i> , <b>2017</b> , 152, 980-989	5.3	1
109	Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2017</b> , 23, S17-S24	1.9	53



108	Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. <i>European Respiratory Review</i> , <b>2017</b> , 26,	9.8	84
107	Does 1-Minute Walk Test Predict Results of 6-Minute Walk Test in Patients With Idiopathic Pulmonary Fibrosis?. <i>Chest</i> , <b>2017</b> , 152, A486	5.3	2
106	Pitfalls in developing new compounds for idiopathic pulmonary fibrosis. <i>Current Opinion in Pulmonary Medicine</i> , <b>2017</b> , 23, 426-431	3	2
105	Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases. <i>Chest</i> , <b>2017</b> , 151, 204-214	5.3	12
104	Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. <i>Lancet Respiratory Medicine</i> , <b>2017</b> , 5, 72-84	35.1	97
103	Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy?. <i>Respiratory Medicine</i> , <b>2017</b> , 122 Suppl 1, S10-S13	4.6	11
102	Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. <i>Lancet Respiratory Medicine</i> , <b>2017</b> , 5, 33-41	35.1	172
101	Incidence and Impact of Gastroparesis After Lung Transplantation. <i>Chest</i> , <b>2017</b> , 152, A1101	5.3	2
100	Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2017</b> , 23, S3-S4	1.9	1
99	Evaluating new treatment options. <i>American Journal of Managed Care</i> , <b>2017</b> , 23, S183-S190	2.1	4
98	Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial. <i>Respiratory Medicine</i> , <b>2016</b> , 117, 254-63	4.6	17
97	Hemothorax following lung transplantation: incidence, risk factors, and effect on morbidity and mortality. <i>Multidisciplinary Respiratory Medicine</i> , <b>2016</b> , 11, 40	3	14
96	Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. <i>European Respiratory Journal</i> , <b>2016</b> , 47, 243-53	13.6	244
95	Lung transplantation in IIP: A review. <i>Respirology</i> , <b>2016</b> , 21, 1173-84	3.6	25
94	Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. <i>BMJ Open Respiratory Research</i> , <b>2016</b> , 3, e000105	5.6	77
93	Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , <b>2016</b> , 47, 1445-51	13.6	33
92	Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. <i>Thorax</i> , <b>2016</b> , 71, 429-35	7.3	112
91	A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 975-82	4.1	3

90	Antacid therapy and idiopathic pulmonary fibrosis: cause for heartburn?. <i>Lancet Respiratory Medicine</i> , <b>2016</b> , 4, 340-1	35.1	2
89	Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. <i>European Respiratory Journal</i> , <b>2016</b> , 48, 843-51	13.6	96
88	Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , <b>2015</b> , 109, 914-22	4.6	55
87	Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. <i>Chest</i> , <b>2015</b> , 148, 196-201	5.3	26
86	Changes in fatigability following intense aerobic exercise training in patients with interstitial lung disease. <i>Respiratory Medicine</i> , <b>2015</b> , 109, 517-25	4.6	12
85	Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 192, 1200-7	10.2	71
84	Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1370-7	13.6	88
83	Pulmonary Hypertension in Sarcoidosis. <i>Clinics in Chest Medicine</i> , <b>2015</b> , 36, 703-14	5.3	30
82	Effect of Pirfenidone on IPF-Related Mortality Outcome Measures in Patients With Idiopathic Pulmonary Fibrosis (IPF): Pooled Data Analysis From the ASCEND and CAPACITY Trials. <i>Chest</i> , <b>2015</b> , 148, 391A	5.3	2
81	Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient: Addressing Key Questions. <i>Chest</i> , <b>2015</b> , 148, 242-252	5.3	29
80	The future of lung transplantation. <i>Chest</i> , <b>2015</b> , 147, 309-316	5.3	30
79	Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study. <i>Chest</i> , <b>2015</b> , 147, 173-179	9.3	58
78	Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis. <i>BMC Pulmonary Medicine</i> , <b>2015</b> , 15, 167	3.5	42
77	Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis. <i>Current Opinion in Pulmonary Medicine</i> , <b>2015</b> , 21, 479-89	3	30
76	Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. <i>Lancet Respiratory Medicine</i> , <b>2015</b> , 3, 473-82	35.1	81
75	Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization. <i>Respiratory Medicine</i> , <b>2015</b> , 109, 1582-8	4.6	9
74	Sustained activation of toll-like receptor 9 induces an invasive phenotype in lung fibroblasts: possible implications in idiopathic pulmonary fibrosis. <i>American Journal of Pathology</i> , <b>2015</b> , 185, 943-57	5.8	32
73	A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 2083-92	59.2	2111



72	All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2014</b> , 189, 825-31 <sup>10,2</sup>	92
71	Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , <b>2014</b> , 108, 1626-32	4.6 55
70	Dysregulation of galectin-3. Implications for Hermansky-Pudlak syndrome pulmonary fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2014</b> , 50, 605-13	5.7 33
69	Response. <i>Chest</i> , <b>2014</b> , 145, 1440-1441	5.3 1
68	Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?. <i>Drug Design, Development and Therapy</i> , <b>2014</b> , 8, 875-85	4.4 19
67	IPF clinical trial design and endpoints. <i>Current Opinion in Pulmonary Medicine</i> , <b>2014</b> , 20, 463-71	3 39
66	Pulmonary hypertension due to lung disease and/or hypoxia. <i>Clinics in Chest Medicine</i> , <b>2013</b> , 34, 695-705	5.3 26
65	Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. <i>Chest</i> , <b>2013</b> , 143, 333-343	5.3 141
64	Glucose transporter-1 distribution in fibrotic lung disease: association with [ <sup>18</sup> F]-2-fluoro-2-deoxyglucose-PET scan uptake, inflammation, and neovascularization. <i>Chest</i> , <b>2013</b> , 143, 1685-1691	5.3 39
63	Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. <i>Current Opinion in Pulmonary Medicine</i> , <b>2013</b> , 19, 466-73	3 36
62	Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. <i>Annals of Internal Medicine</i> , <b>2013</b> , 158, 641-9	8 327
61	The influence of alternative instruction on 6-min walk test distance. <i>Chest</i> , <b>2013</b> , 144, 1900-1905	5.3 28
60	The red cell distribution width as a prognostic indicator in idiopathic pulmonary fibrosis. <i>Chest</i> , <b>2013</b> , 143, 1692-1698	5.3 41
59	Dynamic patient counseling: a novel concept in idiopathic pulmonary fibrosis. <i>Chest</i> , <b>2012</b> , 142, 1005-1010	5.3 31
58	Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations. <i>Lung</i> , <b>2012</b> , 190, 573-8	2.9 13
57	Pulmonary hypertension in idiopathic pulmonary fibrosis: epidemiology, diagnosis and therapeutic implications. <i>Current Respiratory Care Reports</i> , <b>2012</b> , 1, 233-242	7
56	Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor- $\beta$ . <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 186, 740-51	10.2 171
55	Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 186, 712-5	10.2 78

54	Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. <i>European Respiratory Journal</i> , <b>2012</b> , 39, 1520-33	13.6	58
53	Lung size mismatch in bilateral lung transplantation is associated with allograft function and bronchiolitis obliterans syndrome. <i>Chest</i> , <b>2012</b> , 141, 451-460	5.3	70
52	Pulmonary complications of lung transplantation. <i>Chest</i> , <b>2011</b> , 139, 402-411	5.3	45
51	Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. <i>Chest</i> , <b>2011</b> , 140, 221-229	5.3	234
50	Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. <i>Respirology</i> , <b>2011</b> , 16, 439-45	3.6	64
49	The value of computed tomography scanning for the detection of coronary artery disease in patients with idiopathic pulmonary fibrosis. <i>Respirology</i> , <b>2011</b> , 16, 481-6	3.6	28
48	Supranormal expiratory airflow after bilateral lung transplantation is associated with improved survival. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 183, 79-87	10.2	28
47	The HLA class II Allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis. <i>PLoS ONE</i> , <b>2011</b> , 6, e14715	3.7	39
46	Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , <b>2010</b> , 29, 1159-64	5.8	65
45	Comparison of wait times and mortality for idiopathic pulmonary fibrosis patients listed for single or bilateral lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , <b>2010</b> , 29, 1165-71	5.8	61
44	Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , <b>2010</b> , 104, 1035-41	4.6	138
43	Genomic phenotype of non-cultured pulmonary fibroblasts in idiopathic pulmonary fibrosis. <i>Genomics</i> , <b>2010</b> , 96, 134-45	4.3	59
42	Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. <i>Future Cardiology</i> , <b>2010</b> , 6, 19-35	1.3	17
41	Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. <i>Chest</i> , <b>2009</b> , 135, 1455-1461	5.3	122
40	Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 3958-63	11.5	88
39	Prognostic value of the 6min walk test in bronchiolitis obliterans syndrome. <i>Respiratory Medicine</i> , <b>2009</b> , 103, 1816-21	4.6	9
38	Native lung complications in single-lung transplant recipients and the role of pneumonectomy. <i>Journal of Heart and Lung Transplantation</i> , <b>2009</b> , 28, 851-6	5.8	39
37	Pulmonary Hypertension in Interstitial Lung Disease Diagnosis and Management. <i>Clinical Pulmonary Medicine</i> , <b>2009</b> , 16, 252-257	0.3	

36	PH in Patients with Lung Disease and Hypoxia. <i>Advances in Pulmonary Hypertension</i> , <b>2009</b> , 8, 163-171	0.5	1
35	Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , <b>2008</b> , 102, 1305-10	4.6	157
34	Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. <i>Respiration</i> , <b>2008</b> , 76, 288-94	3.7	150
33	Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis. <i>Chest</i> , <b>2008</b> , 133, 640-5	5.3	55
32	Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. <i>Chest</i> , <b>2007</b> , 131, 657-663	5.3	190
31	Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2007</b> , 175, 875-80	10.2	168
30	International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. <i>Journal of Heart and Lung Transplantation</i> , <b>2006</b> , 25, 745-55	5.8	901
29	Reversal of idiopathic pulmonary arterial hypertension and allograft pneumonectomy after single lung transplantation. <i>Chest</i> , <b>2006</b> , 130, 214-7	5.3	22
28	Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. <i>Chest</i> , <b>2006</b> , 129, 746-52	5.3	597
27	Successful lung transplantation from a donor with a saddle pulmonary embolus. <i>Journal of Heart and Lung Transplantation</i> , <b>2005</b> , 24, 1137-9	5.8	9
26	Lung transplantation: disease-specific considerations for referral. <i>Chest</i> , <b>2005</b> , 127, 1006-16	5.3	57
25	Therapeutic intervention: assessing the role of the international consensus guidelines. <i>Chest</i> , <b>2005</b> , 128, 533S-539S	5.3	8
24	Lung transplant candidate selection and clinical outcomes: strategies for improvement in prioritization. <i>Current Opinion in Organ Transplantation</i> , <b>2005</b> , 10, 216-220	2.5	
23	Interferon gamma-1b as therapy for idiopathic pulmonary fibrosis. An inpatient analysis. <i>Respiration</i> , <b>2004</b> , 71, 77-82	3.7	19
22	Sarcoidosis, race, and short-term outcomes following lung transplantation. <i>Chest</i> , <b>2004</b> , 125, 990-6	5.3	47
21	Outcomes of COPD lung transplant recipients after lung volume reduction surgery. <i>Chest</i> , <b>2004</b> , 126, 1569-74	5.3	29
20	Mortality from time of listing for transplantation as an indicator of candidate outcomes. <i>Progress in Transplantation</i> , <b>2004</b> , 14, 29-32	1.1	1
19	Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients. <i>Chest</i> , <b>2003</b> , 123, 1758-63	5.3	61

18	Idiopathic Pulmonary Fibrosis in Transplantation. <i>Chest</i> , <b>2003</b> , 124, 2404-2405	5:3	2
17	Orthotopic Lung Transplant for Sarcoidosis. <i>Chest</i> , <b>2003</b> , 123, 963	5:3	2
16	Using Pharmacovigilance to Assess the Safety of Interferon Gamma-1b in Patients With Severe Idiopathic Pulmonary Fibrosis (IPF). <i>Chest</i> , <b>2003</b> , 124, 193S	5:3	2
15	Bronchiolitis obliterans syndrome: utility of the new guidelines in single lung transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , <b>2003</b> , 22, 427-32	5:8	23
14	Significance of early bronchoscopic airway abnormalities after lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , <b>2003</b> , 22, 583-6	5:8	5
13	Predicting mortality in patients with sarcoidosis awaiting lung transplantation. <i>Chest</i> , <b>2003</b> , 124, 922-8	5:3	35
12	Outcomes for patients with sarcoidosis awaiting lung transplantation. <i>Chest</i> , <b>2002</b> , 122, 233-8	5:3	89
11	Telesupport: just reach out and touch someone. <i>Chest</i> , <b>2002</b> , 122, 1114-6	5:3	
10	Aspergillus and endobronchial abnormalities in lung transplant recipients. <i>Chest</i> , <b>2000</b> , 118, 403-7	5:3	51
9	Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome. <i>Journal of Heart and Lung Transplantation</i> , <b>1999</b> , 18, 1024-6	5:8	25
8	Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trials. <i>Chest</i> , <b>1996</b> , 109, 870-3	5:3	28
7	Work of breathing after extubation. <i>Chest</i> , <b>1995</b> , 107, 204-9	5:3	69
6	Bronchiolitis obliterans in single-lung transplant recipients. <i>Chest</i> , <b>1995</b> , 107, 967-72	5:3	53
5	Spinal aspergillus abscess in a patient with bronchocentric granulomatosis. <i>Journal of Intensive Care Medicine</i> , <b>1995</b> , 10, 45-8	3:3	2
4	Utility of inhaled pentamidine prophylaxis in lung transplant recipients. <i>Chest</i> , <b>1994</b> , 105, 417-20	5:3	25
3	Prediction of minimal pressure support during weaning from mechanical ventilation. <i>Chest</i> , <b>1993</b> , 103, 1215-9	5:3	127
2	Use of Nd:YAG laser in endobronchial Kaposi's sarcoma. <i>Chest</i> , <b>1990</b> , 98, 1299-300	5:3	13
1	Association of D-dimer and fibrinogen magnitude with hypercoagulability by thromboelastography in severe COVID-19		1

